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Background: 
There is reasonably strong evidence that some physical therapy interventions such 
as exercise and manual therapy are effective (compared to minimal or no 
intervention) for patients with low back pain (LBP); however, the effect sizes are 
typically small.6 Many clinicians argue this evidence is at odds with their daily clinical 
experience, which begs the question ‘why the disparity’? There are several reasons 
that likely contribute to small effects in clinical trials of LBP and other 
musculoskeletal conditions. In this viewpoint we will look at which of these reasons 
are beyond our control as clinicians and simply need to be acknowledged and 
understood, and which reasons might provide insights into improving the design of 
future clinical trials of LBP and ultimately deliver better care to our patients. 
 
Many patients with back pain have a favourable natural prognosis: 
There is strong evidence that the prognosis of many patients presenting to primary 
care with LBP is favorable regardless of treatment. A systematic review of the 
prognosis of acute duration LBP found that on average patients’ pain scores (on a 0-
100 scale) reduced from 52 when they presented for care, to 23 at 6 weeks, and 
only 6 out of 100 at one year.2  Even patients who presented with persistent LBP 
improved markedly with average pain intensity dropping from 51/100 to 33/100 over 
the first 6 weeks.2   
 
Clinical trials compare the outcomes of patients allocated to treatment or control 
groups. As many patients with LBP have a favorable prognosis, then even if the 
control group gets minimal or no treatment, the evidence is strong that on average 
they will show substantial improvement, especially if the study sample includes 
patients with acute LBP. In this situation where the control group on average 
recovers well, it is very difficult or even impossible for a treatment to demonstrate 
significant benefits over the control.  It is common (although often not appropriate) 
for clinical trials to consider the benefit from treatment to be ‘clinically important’ if 
the difference between the outcome score for the treatment and control groups is 
greater than a ‘minimal clinically important change’ score. For the outcome of LBP 
intensity minimal clinically important change is frequently reported to be 
approximately 20 points on a 100 point scale.7 If the average pain intensity outcome 
score of the control group is similar or lower than the minimal clinically important 
change score (e.g. 15 points on 100 point scale) then it is virtually impossible for the 
treatment to meet this criteria, regardless of how efficacious the intervention 
actually is.  
 
So how should we respond to the favorable natural prognosis of acute LBP in 
particular? Firstly we need to question the usefulness of conducting further physical 
therapy trials in unselected acute LBP populations. Guidelines recommend simple 
care for people presenting with acute LBP with an option for a review after 1-2 
weeks.5 One option is to design trials which only include patients who do not 
improve markedly over the first 1-2 weeks with simple care. Another option is to 
only include patients whose baseline presentation suggests their prognosis is less 
favorable, using existing prognostic tools.4  Importantly this is not taking away a 
physical therapist’s role but rather changing the role to align with their increasingly 
common role as primary care clinicians. Patients with a favorable prognosis still need 
good advice and reassurance and the opportunity for a review to ensure they are 
progressing well. Until physical therapists are willing to embrace the critical role of 
simple care and review when appropriate, the profession cannot optimize their role 
as a first contact health care provider managing LBP and other musculoskeletal 
conditions.  Clinical trials of physical therapy interventions in patients who are not 
improving well with simple care, or have a less favorable prognosis, would appear 
more clinically important and also have a greater chance of showing larger treatment 
effects. Investigating longer-term outcomes, at least as the primary outcome in 
patients with acute LBP also needs careful thought, given the favorable natural 
clinical course over longer periods of most patients with LBP.  
 
Using patient reported outcomes: 
As a researcher or clinician it is frustrating to see a patient who reports marked 
improvement only to see the failure of the outcome measure to capture this during 
data collection.  A limitation of most currently used outcome measures is that these 
tools are unidimensional, whereas recovery is multidimensional. These tools often 
don’t capture many domains of what physical therapists offer their patients. For 
example, after 3 sessions of physical therapy a patient may have only improved 
slightly with respect to pain intensity or disability (measured with Oswestry Disability 
Index); however, they may now be more confident to manage their back, be more 
physically active and less worried about their back pain. Most treatments patients 
receive are complex, consisting of numerous active ingredients that target multiple 
factors such as pain, function, interference with leisure activities and work/daily 
routine, while also seeking to address patients’ pain-related concerns and level of 
understanding about their condition. Further, although generic health-related quality 
of life measures such as the EQ-5D and SF-36 are available these are not focused on 
back specific treatment targets, and unsurprisingly show lower sensitivity to change 
than back-specific outcome measures.  A challenge for future research is therefore 
to develop multidimensional measures that are sensitive to change for patients with 
LBP and include domains which patients with LBP have prioritized as being 
particularly important and relevant to their experience.  
 
Between group differences and within group changes 
Whereas between-group differences in outcomes are typically reported as being 
small, many trials compare one intervention to another intervention so between-
group differences represent the difference in effectiveness of one approach 
compared to another; rather than simply the effectiveness of the intervention. While 
this may seem relatively obvious it is commonly misunderstood or reported 
incorrectly in trial publications. For example there is strong evidence that most trials 
comparing different types of exercise for chronic LBP find little or no difference in 
effect.3 However, this does not mean that the different exercise types had little or no 
effect, but just that the effects between the different types were similar on average. 
Trials commonly compare a treatment to standard care or minimal care and few 
trials compare one treatment to no treatment. It is difficult to compare one 
treatment for LBP to a no treatment control because there is evidence some 
treatments are effective, thus randomising patients to no treatment is often not 
ethical or practical. Only randomized trials comparing a treatment to non-treatment 
group are really designed to assess the total effect of a treatment. Even placebo 
controlled trials are designed to test particular components of a treatment. Often in 
studies of multimodal treatments used by physical therapists, the placebo treatment 
includes some active elements such as reassurance.   
 
Treatment effects are the average effect in the population 
Most randomized controlled trials involving patients with LBP compare pain and 
disability outcomes between groups, often at key time points. Importantly this is a 
comparison of the average score (or change) for the outcome across all people in 
the groups. It is widely accepted that patients with LBP are heterogeneous in many 
regards and that back pain is a complex multifactorial condition.  While it would be 
ideal if one single, simple intervention was highly effective across this heterogeneous 
population, this does not seem likely given our understanding of LBP and neither is 
this approach supported by the clinical trial evidence of thousands of trials that have 
investigated mostly unidimensional interventions in patients with non-specific LBP.   
This problem of heterogeneity has been known for quite a while and identifying 
groups of patients who are more homogenous and respond best to particular 
interventions has been identified as the number one priority in back pain research.1 
Unfortunately these trials need to be very large and are expensive to conduct. As a 
result, few have been conducted, and little evidence is currently available to inform 
whether better matching of patients to interventions can increase effect sizes.8,9 
Some promising findings exist and replication studies are under way to assess the 
generalisability of these early findings. A related but different approach to this 
problem of heterogeneity is to develop more multidimensional treatment approaches 
that address a range of potential contributors to LBP and can be tailored to an 
individual patient’s needs. Interestingly this is what many clinicians report they do in 
clinical practice; however, few clinical trials have followed this approach possibly due 
to challenges in designing and interpreting the results of such trials.  
 
Need for a better understanding of patient phenotypes and treatment 
mechanisms 
Should it really be surprising that treatment effect sizes for LBP are small when the 
nociceptive source and causes for LBP remain poorly understood and there is no 
clear theoretical framework for how most interventions might work?  A physical 
therapist may take for granted that exercise should help LBP (and it does a little on 
average), but what is the biological rationale or mechanism for this? We debate and 
investigate the best type of exercise; however, without a strong understanding of 
the underlying causes (phenotypes) and hypothesised treatment targets it is difficult 
to empirically test who an intervention might work best for or how it might be 
working.  Arguably there is a need to stop doing more clinical trials in a condition we 
don’t really understand using interventions that we don’t have a strong rational for 
and put more effort into better understanding the different causes and types of 
patients with  LBP and the mechanisms of the interventions available.  If this was 
achieved, some existing treatments may be found to produce larger effects when 
targeted to the right patients. Other treatments may be discarded as they have no 
logical basis, and new more effective treatments may also be developed.  
 
The recent interest in bacterial infection (Modic changes) as a potential cause of LBP 
in some people is an example of how important it is to investigate both the causes of 
LBP and the mechanisms by which treatments work. The identification of a 
phenotype of LBP (e.g. due to likely bacterial infection) results in a more 
homogenous group in whom a more logical treatment can be tested. If the 
treatment is shown to be more effective in those in this phenotype than those not in 
the phenotype, the phenotype is a moderator of treatment. It is also important to 
test or confirm if the treatment is working in the manner hypothesised (mediation 
analysis). In the example of using antibiotics for LBP, it would be important to test if 
the improvements in outcome are actually due to reduction in bacterial infection or 
due to some other mechanism such as reduction in inflammation.  
 
We suggest that future research needs to focus on firstly, developing a better 
understanding about the causes and phenotypes (clinically important subgroups) of 
LBP and secondly, testing if treatments are working in the manner hypothesised to 
have a greater chance of identifying more effective interventions for LBP. 
 
Summary 
The widely reported small effects of physical therapy interventions for LBP need to 
be understood and interpreted in the context of the natural course of LBP and the 
inherent limitations of clinical trials especially in complex health conditions. The 
findings should motivate the profession to reconsider its role as a primary health 
care professional, with much more to offer than highly effective interventions. 
Researchers should be challenged to better understand the causes of LBP and the 
mechanisms by which treatments work so more effective and individualised 
treatments can be developed in the future.  
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